Tuesday, July 02, 2024
N-Power Medicine, in collaboration with Merck (known as MSD outside the United States and Canada), aims to enhance participation in oncology research. N-Power's platform integrates technology, AI, and on-site research staff to streamline clinical research alongside routine patient care. This collaboration seeks to establish oncology practices within N-Power's Clinical Research Network as innovative research sites, increasing access to trials for eligible patients.
N-Power, emphasized the partnership's importance in expanding inclusive clinical research in oncology. Merck's Senior Vice President of Oncology Clinical Development, Marjorie Green, M.D., highlighted the potential to innovate cancer care and deliver new therapies needed urgently by patients.
Recently, N-Power Medicine completed an initial close of its Series B funding round, raising $72 million to expand its network of oncology clinics and collaborations with biopharmaceutical companies. This funding, led by Merck Global Health Innovation Fund, underscores N-Power's commitment to integrating clinical research into patient care.
Source: npowermedicine.com
